Replies to post #251810 on Biotech Values

[Whalatane]

Thx Jbog Just to be clear ...and it's none of my business so ignore if necessary ...the cysts were liquid filled ? I thought that was one of the markers of ADPKD

You wrote
.

After a couple tests they determined they were liquid filled rather than solid so I was basically in the clear.

A Perplexity search
The cysts in autosomal dominant polycystic kidney disease (ADPKD) are fluid-filled sacs that develop within the kidneys.
The symptoms of ADPKD are caused by the growth of these fluid-filled cysts in the kidneys. As the cysts expand, they can cause the kidneys to become enlarged and gradually lose function over time.
The cyst fluid itself contains various substances that promote further cyst growth and expansion. Studies have shown that the cyst fluid stimulates cellular proliferation, fluid secretion, and cyst formation when added to cultured renal epithelial cells. The cyst fluid contains potent substances that augment biological processes leading to progressive cyst expansion in ADPKD.
So in summary, the hallmark of ADPKD is the development of numerous liquid-filled cysts within the kidneys, which are the primary cause of the disease manifestations and complications as the cysts progressively enlarge over time.

Kiwi

[Whalatane]

Jbog. re your comment

The shares immediately jumped to $2.80 and has leaked down to the lower $2 level.

Last week they said they would raise another $50m ...ie dilute existing shareholders by about .45 c a share .
Just my layman's take
Data looks good ...so far
Kiwi
JMO

[vinmantoo]

Around 2017 I was having neck and back problems and went in for a MRI. The next morning my personnel doctor (not back doc) called and told me I was loaded with Kidney Cysts on the right side and wanted them investigated. After a couple tests they determined they were liquid filled rather than solid so I was basically in the clear.

During this time period I researched autosomal dominant polycystic kidney disease (ADPKD) and like Kiwi said, there's nothing out there. I did come across Regulis and the trials they were performing with a drug called RGLS4326 was showing very good P1 and P2 control. I bought a couple thousand share on a hunch at $7 per share.

After they finished their 3rd MAD dose,which the results were fantastic, the bad news hit. Some rodents in their pre-clinical data have exhibited toxicity after 4 years, Of course the stock crushed.

Regulis responded that they were able to find the problem and promised a fix. Soon after they came out with RGLS8429 which they promised would be safe and more powerful.

jbog, thanks for the detailed response. Glad your test were good news. I will take a closer look. All I knew before your comment is that they are using miRNA modulation as their MOA. That mechanism certainly presents possibilities of treatment of a broad spectrum of diseases. A long time ago I had a colleague who found a puzzling phenomenon, where a region down stream of a C. elegans gene was affecting expression of a different gene on another chromosome. It was puzzling because the down stream region didn't code for a protein and his career suffered. He didn't get tenure so had to move on to another University. Once it was discovered that the downstream region he was working on coded for a small RNA (i.e. miRNA), it made his career take off. Lots of serendipity in science. As far as RGLS, RGLS4326 is their only drug in trials so far. Any idea when they project other areas they are working will enter trials? I guess I need to listen to the latest CC. Good luck.

Thanks also to Kiwi as well for his response.